Google AI
NewsPronto

 

PR Newswire

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

  • Written by: PR Newswire Asia - News Pronto RSS

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the...

Read more: Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic...